PEN

Over the past six months, Penumbra, Inc.'s (PEN) stock price decreased by 5.34%, with a 52-week range between $221.26 and $362.41. A key event was the January 2026 announcement of Boston Scientific's acquisition of Penumbra for approximately $14.5 billion, valuing each share at $374. Q1 2026 earnings were released on May 6, 2026. Q2 2026 earnings, released on July 30, 2026, reported an EPS of $0.88 against an estimate of $1.16, a 24.30% surprise miss, which led to a 0.74% decrease in the stock price. Revenue for Q2 2026 was $390.0 million, up 14.9% year-over-year, driven by higher sales of thrombectomy and embolization/access products. Due to the pending acquisition, Penumbra did not provide financial guidance for the full year 2026.